October 12, 2026
FDA approves Asahi Kasei’s Hovilpri for refractory HSV
The US Food and Drug Administration (FDA) has approved Asahi Kasei Therapeutics’ Hovilpri (pritelivir) 100mg tablets to treat refractory mucocutaneous herpes simplex virus (HSV) lesions in immunocompromised adults.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.







